Arcutis Biotherapeutics, Inc.
Public company- Headquarters
- WESTLAKE VILLAGE, California
- Ticker
- ARQT
- CIK
- 0001787306
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Class II directorRobert Scott | Oct 28, 2026 | Appointed |
| chief commercial officerL. Todd Edwards | Aug 5, 2026 | Departed |
| interim executive vice presidentRobert Lisicki | Aug 5, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive appointment
Class II director appointed: Robert Scott
Robert Scott was named Class II director of Arcutis Biotherapeutics, Inc., effective October 23, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 28, 2026Role: Class II director
- Executive departure
chief commercial officer departs: L. Todd Edwards
L. Todd Edwards, chief commercial officer of Arcutis Biotherapeutics, Inc., resigns the role, effective August 21, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 5, 2026Role: chief commercial officer
- Executive appointment
interim executive vice president appointed: Robert Lisicki
Robert Lisicki was named interim executive vice president of Arcutis Biotherapeutics, Inc., effective August 17, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 5, 2026Role: interim executive vice president
Last verified Nov 8, 2026